Sub-lethally irradiated cohorts of mice were injected with GFP+  MLL-AF9 AML blasts and cohorts of comparable disease burden (Supplementary Fig. 2F) were treated with vehicle, single drugs or combination for 21 days. The gene discussed is KMT2A; the disease is acute myeloid leukemia.